• Brett E Youngerman, Matei A Banu, Farhan Khan, Guy M McKhann, Catherine A Schevon, Jonathan R Jagid, Iahn Cajigas, Christian B Theodotou, Andrew Ko, Robert Buckley, Jeffrey G Ojemann, John W Miller, Adrian W Laxton, Daniel E Couture, Gautam S Popli, Vivek P Buch, Casey H Halpern, Scheherazade Le, Ashwini D Sharan, Michael R Sperling, Ashesh D Mehta, Dario J Englot, Joseph S Neimat, Peter E Konrad, Sameer A Sheth, Elliot G Neal, Fernando L Vale, Kathryn L Holloway, Ellen L Air, Jason M Schwalb, Pierre-François D'Haese, and Chengyuan Wu.
• Department of Neurological Surgery, Columbia University, New York, New York, USA bey2103@cumc.columbia.edu.
• J. Neurol. Neurosurg. Psychiatr. 2023 Nov 1; 94 (11): 879886879-886.

BackgroundMagnetic resonance-guided laser interstitial thermal therapy (MRgLITT) is a minimally invasive alternative to surgical resection for drug-resistant mesial temporal lobe epilepsy (mTLE). Reported rates of seizure freedom are variable and long-term durability is largely unproven. Anterior temporal lobectomy (ATL) remains an option for patients with MRgLITT treatment failure. However, the safety and efficacy of this staged strategy is unknown.MethodsThis multicentre, retrospective cohort study included 268 patients consecutively treated with mesial temporal MRgLITT at 11 centres between 2012 and 2018. Seizure outcomes and complications of MRgLITT and any subsequent surgery are reported. Predictive value of preoperative variables for seizure outcome was assessed.ResultsEngel I seizure freedom was achieved in 55.8% (149/267) at 1 year, 52.5% (126/240) at 2 years and 49.3% (132/268) at the last follow-up ≥1 year (median 47 months). Engel I or II outcomes were achieved in 74.2% (198/267) at 1 year, 75.0% (180/240) at 2 years and 66.0% (177/268) at the last follow-up. Preoperative focal to bilateral tonic-clonic seizures were independently associated with seizure recurrence. Among patients with seizure recurrence, 14/21 (66.7%) became seizure-free after subsequent ATL and 5/10 (50%) after repeat MRgLITT at last follow-up≥1 year.ConclusionsMRgLITT is a viable treatment with durable outcomes for patients with drug-resistant mTLE evaluated at a comprehensive epilepsy centre. Although seizure freedom rates were lower than reported with ATL, this series represents the early experience of each centre and a heterogeneous cohort. ATL remains a safe and effective treatment for well-selected patients who fail MRgLITT.© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

15 keywords...

hide…